GlassScriptPhysician profile
Victor W Matthews
NPI 1457363541
$8,110.69
in general payments reported to CMS, 2019-2025
33 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,162 · 2020: $388 · 2021: $11.97 · 2022: $43.90 · 2023: $69.75 · 2024: $166 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $5,456.03 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $311.21 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $283.51 | 2019-2020 | |
| Amgen INC. | $248.99 | 2019-2025 | Tepezza, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $206.70 | 2025 | |
| Cequr Corporation | $198.64 | 2025 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $176.58 | 2025 | Tlando |
| Lilly USA, LLC | $172.32 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Insulet Corporation | $148.24 | 2019-2024 | Omnipod |
| Ascensia Diabetes Care US INC. | $122.91 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $77.81 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.18 | 2019-2025 | Jardiance |
| Medtronic Minimed, INC. | $71.19 | 2019 | |
| Merck Sharp & Dohme LLC | $65.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $53.14 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $48.28 | 2025 | Twiist |
| Shire North American Group INC | $40.47 | 2019 | |
| Recordati_rare_diseases_inc. | $37.56 | 2025 | Isturisa |
| Amarin Pharma, INC. | $33.35 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $29.18 | 2025 | |
| Amneal Pharmaceuticals LLC | $24.58 | 2025 | Unithroid |
| Novartis Pharmaceuticals Corporation | $24.16 | 2024 | |
| Ascendis Pharma Endocrinology INC | $23.78 | 2025 | Yorvipath |
| Esperion Therapeutics, INC. | $21.51 | 2025 | Nexletol |
| Acella Pharmaceuticals, LLC | $21.24 | 2025 | NP Thyroid 60 |
| Corcept Therapeutics | $21.22 | 2025 | Korlym |
| Kyowa Kirin, INC. | $20.47 | 2025 | |
| Antares Pharma, INC. | $20.00 | 2019 | |
| Valeritas, INC. | $19.76 | 2019 | |
| Beta Bionics, INC. | $17.00 | 2024 | Ilet Bionic Pancreas |
| Janssen Pharmaceuticals, INC | $15.18 | 2020 | |
| Madrigal Pharmaceuticals | $15.17 | 2025 | Rezdiffra |
| Dexcom, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.